Characterization of nanoparticles-based vaccines for COVID-19
Source abstract
Abstract
Several vaccines against COVID-19 use nanoparticles to protect the antigen cargo (either proteins or nucleic acids), increase the immunogenicity and ultimately the efficacy. The characterization of these nanomedicines is challenging due to their intrinsic complexity and requires the use of multidisciplinary techniques and competencies. The accurate characterization of nanovaccines can be conceptualized as a combination of physicochemical, immunological and toxicological assays. This will help to address key challenges in the preclinical characterization, will guide the rapid development of safe and effective vaccines for current and future health crises, and will streamline the regulatory process.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: SARS-CoV-2 and COVID-19 Research · Immunotherapy and Immune Responses · vaccines and immunoinformatics approaches
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (55)
Show source-provided references
1. COVID-19 Vaccine Tracker and Landscape (WHO, accessed 4 August 2021); https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines
2. Kisby, T., Yilmazer, A. & Kostarelos, K. Reasons for success and lessons learnt from nanoscale vaccines against COVID-19. Nat. Nanotechnol. 16, 843–850 (2021).10.1038/s41565-021-00946-9 ↗
3. Hassett, K. J. et al. Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines. Mol. Ther. Nucleic Acids 15, 1–11 (2019).10.1016/j.omtn.2019.01.013 ↗
4. Comirnaty Assessment Report EMA\/707383\/2020 (EMA, 2021); https://www.ema.europa.eu/en/documents/assessment-report/comirnaty-epar-public-assessment-report_en.pdf
5. COVID-19 Vaccine Moderna Assessment Report EMA/15689/2021 (EMA, 2021); https://www.ema.europa.eu/en/documents/assessment-report/spikevax-previously-covid-19-vaccine-moderna-epar-public-assessment-report_en.pdf
6. Pfizer-BioNTech COVID-19 FDA Briefing Document (FDA, 2020); https://www.fda.gov/media/144245/download
7. Mahase, E. Covid-19: UK government asks regulator to assess Oxford vaccine as questions are raised over interim data. Brit. Med. J. 371, m4670 (2020).10.1136/bmj.m4670 ↗
8. Knoll, M. D. & Wonodi, C. Oxford–AstraZeneca COVID-19 vaccine efficacy. The Lancet 397, 72–74 (2021).10.1016/S0140-6736(20)32623-4 ↗
9. Rappuoli, R. & De Gregorio, E. Editorial overview: vaccines: novel technologies for vaccine development. Curr. Opin. Immunol. 41, v–vii (2016).10.1016/j.coi.2016.07.001 ↗
10. Calzolai, L., Gioria, S. & Magrì, D. Nanoparticle-Based Vaccines in Clinical Trial/Use for COVID-19 and Licensed for Other Pathogens (European Commission, 2021); https://data.jrc.ec.europa.eu/dataset/1575f3b3-f8e6-4f6c-a296-77e8d1be4ee1#citation
11. Lindsay, K. E. et al. Visualization of early events in mRNA vaccine delivery in non-human primates via PET–CT and near-infrared imaging. Nat. Biomed. Eng. 3, 371–380 (2019).10.1038/s41551-019-0378-3 ↗
12. Hall, J. B., Dobrovolskaia, M. A., Patri, A. K. & McNeil, S. E. Characterization of nanoparticles for therapeutics. Nanomedicine 2, 789–803 (2007).10.2217/17435889.2.6.789 ↗
13. Drug Products, Including Biological Products, that Contain Nanomaterials—Guidance for Industry (FDA, 2017); https://www.fda.gov/regulatory-information/search-fda-guidance-documents/drug-products-including-biological-products-contain-nanomaterials-guidance-industry
14. Faria, M. et al. Minimum information reporting in bio–nano experimental literature. Nat. Nanotechnol. https://doi.org/10.1038/s41565-018-0246-4 (2018).10.1038/s41565-018-0246-4 ↗
15. Leong, H. S. et al. On the issue of transparency and reproducibility in nanomedicine. Nat. Nanotechnol. 14, 629–635 (2019).10.1038/s41565-019-0496-9 ↗
16. Hassett, K. J. et al. Impact of lipid nanoparticle size on mRNA vaccine immunogenicity. J. Control. Release 335, 237–246 (2021).10.1016/j.jconrel.2021.05.021 ↗
17. Caputo, F. et al. Measuring particle size distribution and mass concentration of nanoplastics and microplastics: addressing some analytical challenges in the sub-micron size range. J. Colloid Interface Sci. https://doi.org/10.1016/j.jcis.2020.12.039 (2021).10.1016/j.jcis.2020.12.039 ↗
18. Parot, J., Caputo, F., Mehn, D., Hackley, V. A. & Calzolai, L. Physical characterization of liposomal drug formulations using multi-detector asymmetrical-flow field flow fractionation. J. Control. Release 320, 495–510 (2020).10.1016/j.jconrel.2020.01.049 ↗
19. Mildner, R. et al. Improved multidetector asymmetrical-flow field-flow fractionation method for particle sizing and concentration measurements of lipid-based nanocarriers for RNA delivery. Eur. J. Pharm. Biopharm. 163, 252–265 (2021).10.1016/j.ejpb.2021.03.004 ↗
20. Mehn, D., Capomaccio, R., Gioria, S., Gilliland, D. & Calzolai, L. Analytical ultracentrifugation for measuring drug distribution of doxorubicin loaded liposomes in human serum. J. Nanopart. Res. 22, 1–7 (2020).10.1007/s11051-020-04843-5 ↗
21. Tran, J. C. et al. Mapping intact protein isoforms in discovery mode using top-down proteomic. Nature 480, 254–258 (2011).10.1038/nature10575 ↗
22. Tanguay, R. L. & Gallie, D. R. Translational efficiency is regulated by the length of the 3′ untranslated region. Mol. Cell. Biol. 16, 146–156 (1996).10.1128/MCB.16.1.146 ↗
23. Beverly, M., Dell, A., Parmar, P. & Houghton, L. Label-free analysis of mRNA capping efficiency using RNase H probes and LC–MS. Anal. Bioanal. Chem. 408, 5021–5030 (2016).10.1007/s00216-016-9605-x ↗
24. Varenne, F. et al. Standardization and validation of a protocol of zeta potential measurements by electrophoretic light scattering for nanomaterial characterization. Colloids Surf. https://www.sciencedirect.com/science/article/abs/pii/S0927775715301862 (2015).10.1016/j.colsurfa.2015.08.044 ↗
25. Reijenga, J., Van Hoof, A., Van Loon, A. & Teunissen, B. Development of methods for the determination of pKa values. Anal. Chem. Insights https://journals.sagepub.com/doi/full/10.4137/ACI.S12304 (2013).10.4137/ACI.S12304 ↗
26. Capua, I. & Giaquinto, C. The unsung virtue of thermostability. Lancet 397, 1346 (2021).10.1016/S0140-6736(21)00526-2 ↗
27. Guerrini, G. et al. Physicochemical characterization cascade of nanoadjuvant–antigen systems for improving vaccines. Vaccines 9, 544 (2021).10.3390/vaccines9060544 ↗
28. \Durowoju, I. B., Bhandal, K. S., Hu, J., Carpick, B. & Kirkitadze, M. Differential scanning calorimetry—a method for assessing the thermal stability and conformation of protein antigen. J. Vis. Exp. https://www.jove.com/t/55262/differential-scanning-calorimetry-method-for-assessing-thermal (2017).10.3791/55262 ↗
29. Crist, R. M. et al. Common pitfalls in nanotechnology: lessons learned from NCI’s Nanotechnology Characterization Laboratory. Integr. Biol. 5, 66–73 (2013).10.1039/c2ib20117h ↗
30. Sallusto, F. & Lanzavecchia, A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med. 179, 1109–1118 (1994).10.1084/jem.179.4.1109 ↗
31. Hubo, M. et al. Costimulatory molecules on immunogenic versus tolerogenic human dendritic cells. Front. Immunol. 4, 82 (2013).10.3389/fimmu.2013.00082 ↗
32. Cupedo, T., Stroock, A. D. & Coles, M. C. Application of tissue engineering to the immune system: development of artificial lymph nodes. Front. Immunol. 3, 3389 (2012).10.3389/fimmu.2012.00343 ↗
33. Wagar, L. E. et al. Modeling human adaptive immune responses with tonsil organoids. Nat. Med. 27, 125–135 (2021).10.1038/s41591-020-01145-0 ↗
34. Haile, L. A. et al. Cell based assay identifies TLR2 and TLR4 stimulating impurities in interferon beta. Sci. Rep. 7, 10490 (2017).10.1038/s41598-017-09981-w ↗
35. Della Camera, G. et al. A step-by-step approach to improve clinical translation of liposome-based nanomaterials, a focus on innate immune and inflammatory responses. Int. J. Mol. Sci 22, 820 (2021).10.3390/ijms22020820 ↗
36. Szebeni, J. & Moghimi, S. M. Liposome triggering of innate immune responses: a perspective on benefits and adverse reactions. J. Liposome Res. 19, 85–90 (2009).10.1080/08982100902792855 ↗
37. Huynh, A., Kelton, J. G., Arnold, D. M., Daka, M. & Nazy, I. Antibody epitopes in vaccine-induced immune thrombotic thrombocytopaenia. Nature 596, 565–569 (2021).10.1038/s41586-021-03744-4 ↗
38. Greinacher, A. et al. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N. Engl. J. Med. 384, 2092–2101 (2021).10.1056/NEJMoa2104840 ↗
39. Non-Clinical Evaluation of Vaccines (WHO); https://www.who.int/teams/health-product-policy-and-standards/standards-and-specifications/vaccine-standardization/non-clinical-evaluation-of-vaccines
40. Manual of Laboratory Methods for Testing of Vaccines used in the WHO Expanded Programme on Immunization (WHO, 1997); https://apps.who.int/iris/handle/10665/63576
41. Laboratory Biosafety Manual 4th edn (WHO, 2020); https://www.who.int/publications/i/item/9789240011311
42. Pardi, N. et al. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. J. Control. Release 217, 345–351 (2015).10.1016/j.jconrel.2015.08.007 ↗
43. Tan, C. W. et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction. Nat. Biotechnol. 38, 1073–1078 (2020).10.1038/s41587-020-0631-z ↗
44. Fiorino, F., Pettini, E., Pozzi, G., Medaglini, D. & Ciabattini, A. Prime-boost strategies in mucosal immunization affect local IgA production and the type of the response. Front. Immunol 4, 128 (2003).
45. Medaglini, D. et al. In vivo activation of naive CD4+ T cells in nasal mucosa-associated lymphoid tissue following intranasal immunization with recombinant Streptococcus gordonii. Infect. Immun. 74, 2760–2766 (2006).10.1128/IAI.74.5.2760-2766.2006 ↗
46. Ciabattini, A. Evidence of SARS-CoV-2-specific memory B cells six months after vaccination with the BNT162b2 mRNA vaccine. Front. Immunol 12, 3389 (2021).10.3389/fimmu.2021.740708 ↗
47. Pastore, G. et al. Optimized protocol for the detection of multifunctional epitope-specific CD4+ T cells combining MHC-II tetramer and intracellular cytokine staining technologies. Front. Immunol. 10, 2304 (2019).10.3389/fimmu.2019.02304 ↗
48. Lucchesi, S. et al. Computational analysis of multiparametric flow cytometric data to dissect B cell subsets in vaccine studies. Cytometry A 97, 259–267 (2020).10.1002/cyto.a.23922 ↗
49. Gilbert, P. B. et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science 375, 43–50 (2022).10.1126/science.abm3425 ↗
50. DiPiazza, A. T. et al. COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge. Immunity 54, 1869–1882 (2021).10.1016/j.immuni.2021.06.018 ↗
51. Jiang, R.-D. et al. Pathogenesis of SARS-CoV-2 in transgenic mice expressing human angiotensin-converting enzyme 2. Cell 182, 50–58 (2020).10.1016/j.cell.2020.05.027 ↗
52. Urano, E. et al. COVID-19 cynomolgus macaque model reflecting human COVID-19 pathological conditions. Proc. Natl. Acad. Sci. USA 118, e210484711 (2021).10.1073/pnas.2104847118 ↗
53. Ciabattini, A. et al. Vaccination in the elderly: the challenge of immune changes with aging. Semin. Immunol. 40, 83–94 (2018).10.1016/j.smim.2018.10.010 ↗
54. Ciabattini, A. et al. Shelter from the cytokine storm: pitfalls and prospects in the development of SARS-CoV-2 vaccines for an elderly population. Semin. Immunopathol. 42, 619–634 (2020).10.1007/s00281-020-00821-0 ↗
55. Jansen, K. U. & Anderson, A. S. The role of vaccines in fighting antimicrobial resistance (AMR). Hum. Vaccin. Immunother. 14, 2142–2149 (2018).10.1080/21645515.2018.1476814 ↗